Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Upadacitinib

FDA-approved product (tablet, extended release, oral), marketed as Rinvoq, Rinvoq Lq.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Upadacitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Upadacitinib. Its therapeutic class is shown instead.

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Upadacitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Upadacitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • RA-PRO PRAGMATIC TRIAL

    NCT04692493 · start 2021-09-22

    Registered record
    Registry ID
    NCT04692493
    Conditions
    Rheumatoid Arthritis
    Interventions
    targeted synthetic DMARD class; non-TNFi-biologic class
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-09-22
    Completion
    2029-07-31
    Enrolment
    924

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventiontargeted synthetic DMARD class; non-TNFi-biologic class
    PhasePhase 3
    Registry statusRecruiting

  • Replication of the Heads Up Atopic Dermatitis Trial With Registry Data

    NCT06937788 · start 2021-08-02

    Registered record
    Registry ID
    NCT06937788
    Conditions
    Atopic Dermatitis
    Interventions
    Upadacitinib; Dupilumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-08-02
    Completion
    2026-08-26
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionUpadacitinib; Dupilumab
    PhaseNot recorded
    Registry statusTerminated

  • Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

    NCT04927975 · start 2021-06-30

    Registered record
    Registry ID
    NCT04927975
    Conditions
    Non-Segmental Vitiligo
    Interventions
    Upadacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-06-30
    Completion
    2023-08-29
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Segmental Vitiligo
    InterventionUpadacitinib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate

    NCT05121298 · start 2021-01-12

    Registered record
    Registry ID
    NCT05121298
    Conditions
    Rheumatoid Arthritis; JAK Inhibitor; Musculoskeletal Ultrasound; Biomarker
    Interventions
    upadacitinib 15mg/day
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-01-12
    Completion
    2024-09-30
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis; JAK Inhibitor; Musculoskeletal Ultrasound; Biomarker
    Interventionupadacitinib 15mg/day
    PhasePhase 3
    Registry statusUnknown

  • Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

    NCT04505410 · start 2020-09-18

    Registered record
    Registry ID
    NCT04505410
    Conditions
    Ulcerative Colitis
    Interventions
    A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy; Advanced therapy only without dietary intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-18
    Completion
    2023-12-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionA plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy; Advanced therapy only without dietary intervention
    PhasePhase 3
    Registry statusCompleted

  • Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets

    NCT04340115 · start 2020-04-24

    Registered record
    Registry ID
    NCT04340115
    Conditions
    Rheumatoid Arthritis (RA)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-04-24
    Completion
    2025-08-15
    Enrolment
    4,211

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis (RA)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis

    NCT04267536 · start 2020-02-06

    Registered record
    Registry ID
    NCT04267536
    Conditions
    Rheumatoid Arthritis (RA)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-06
    Completion
    2022-02-01
    Enrolment
    534

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis (RA)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

    NCT03725007 · start 2019-06-24

    Registered record
    Registry ID
    NCT03725007
    Conditions
    Juvenile Idiopathic Arthritis (JIA)
    Interventions
    Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2019-06-24
    Completion
    2029-03
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJuvenile Idiopathic Arthritis (JIA)
    InterventionUpadacitinib
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

    NCT03646604 · start 2019-01-31

    Registered record
    Registry ID
    NCT03646604
    Conditions
    Atopic Dermatitis
    Interventions
    Upadacitinib (ABT-494)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-31
    Completion
    2024-08-29
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionUpadacitinib (ABT-494)
    PhasePhase 1
    Registry statusCompleted

  • Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

    NCT05674695 · start 2019-01-01

    Registered record
    Registry ID
    NCT05674695
    Conditions
    Dermatitis, Atopic
    Interventions
    Ciclosporin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2019-01-01
    Completion
    2029-01-01
    Enrolment
    2,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionCiclosporin
    PhaseNot recorded
    Registry statusRecruiting

  • Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

    NCT03569293 · start 2018-08-13

    Registered record
    Registry ID
    NCT03569293
    Conditions
    Atopic Dermatitis
    Interventions
    Placebo for Upadacitinib; Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-13
    Completion
    2025-10-10
    Enrolment
    912

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPlacebo for Upadacitinib; Upadacitinib
    PhasePhase 3
    Registry statusCompleted

  • A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

    NCT02955212 · start 2018-01-03

    Registered record
    Registry ID
    NCT02955212
    Conditions
    Rheumatoid Arthritis (RA)
    Interventions
    Upadacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-03
    Completion
    2020-09-03
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis (RA)
    InterventionUpadacitinib; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

    NCT03345849 · start 2017-12-07

    Registered record
    Registry ID
    NCT03345849
    Conditions
    Crohn's Disease
    Interventions
    Upadacitinib; Placebo for Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-07
    Completion
    2022-01-13
    Enrolment
    526

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionUpadacitinib; Placebo for Upadacitinib
    PhasePhase 3
    Registry statusCompleted

  • A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

    NCT03178487 · start 2017-10-24

    Registered record
    Registry ID
    NCT03178487
    Conditions
    Ankylosing Spondylitis (AS)
    Interventions
    Upadacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-10-24
    Completion
    2022-02-17
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnkylosing Spondylitis (AS)
    InterventionUpadacitinib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

    NCT03006068 · start 2017-01-31

    Registered record
    Registry ID
    NCT03006068
    Conditions
    Ulcerative Colitis (UC)
    Interventions
    Upadacitinib (ABT-494); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-01-31
    Completion
    2027-07
    Enrolment
    950

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis (UC)
    InterventionUpadacitinib (ABT-494); Placebo
    PhasePhase 3
    Registry statusActive not recruiting